-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Rongchang Biotech announced that recently "Taltazep" has been the first to be online in Shandong.
According to the drug instructions, the recommended dosage of this product is 160 mg/time, once a week, and the annual treatment cost is about 268,900 without counting the donation.
As the world's first new dual-target biologic drug approved for the treatment of systemic lupus erythematosus, tatacept inhibits the overexpression of the two cytokines BLyS and APRIL at the same time, increasing the effectiveness of the treatment while improving the safety of the drug .
The key clinical research results showed that the systemic lupus erythematosus response index (SRI) of the high-dose tytacept for 48 weeks was significantly higher than that of the placebo control group (79.
In November 2019, CDE accepted the marketing application of Taltazep for injection in the treatment of systemic lupus erythematosus, and the application was included in the priority review process the following month.
It is worth noting that Tatacept has not only achieved an important breakthrough in the treatment of systemic lupus erythematosus, but also has been used in the treatment of IgA nephritis, Sjogren’s syndrome, optic neuromyelitis, multiple sclerosis and myasthenia gravis.
Note: The original text has been deleted